Antiviral activity of nucleoside analogues against norovirus

Verónica P Costantini1*, Tony Whitaker2, Leslie Barclay1, David Lee1, Tamara R McBrayer2, Raymond F Schinazi3, Jan Vinjé1

1Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
2RFS Pharma, LLC, Tucker, GA, USA
3Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, GA, USA

*Corresponding author e-mail: vcostantini@cdc.gov

Background: Norovirus (NoV) is the leading cause of epidemic gastroenteritis worldwide. The lack of a cell culture has significantly hampered the development of effective therapies against human NoV. Clinically approved nucleoside and non-nucleoside analogues have been used successfully against RNA viruses.

Methods: In this study, we evaluated the efficacy of four nucleoside analogues (2′-C-MeC, 2′-F-2′-C-MeC, β-D-N(4)-hydroxycytidine [NHC] and lamivudine) on Norwalk virus (NV) RNA levels and protein expression in NV replicon-harbouring cells (HG23 cells), and their efficacy in blocking murine norovirus (MNV) replication in RAW 264.7 cells.

Results: 2′-C-MeC and 2′-F-2′-C-MeC reduced MNV RNA levels and infectivity in RAW 264.7 cells in a concentration- and time-dependent manner. The median effective concentrations (EC50) of 2′-C-MeC and 2′-F-2′-C-MeC were 6.9 μM and 12.7 μM, respectively. 2′-C-MeC, 2′-F-2′-C-MeC and NHC reduced NV RNA levels and protein expression in HG23 cells. For the NV replicon, the EC50 of 2′-C-MeC (1.3 μM) was comparable to the antiviral activity of NHC (1.5 μM) and twofold more potent than 2′-F-2′-C-MeC (3.2 μM). The combination of 2′-C-MeC/ribavirin resulted in modest synergistic activity, whereas NHC/ribavirin was antagonistic for NV replication in HG23 cells.

Conclusions: The antiviral activity of 2′-C-MeC against strains of two different NoV genogroups and the low EC50 suggest that this nucleoside analogue may be effective against the more prevalent GII NoVs. In the absence of a vaccine, antiviral agents could be an effective intervention to control the spread of human NoV in populations at a high risk for NoV disease.

Introduction

Norovirus (NoV) is the leading cause of epidemic gastroenteritis in people of all age groups worldwide and the second most common cause of severe gastroenteritis in hospitalized children less than five years old [1]. In the United States, NoVs are the most important cause of foodborne illness, accounting for more cases than all bacterial enteric pathogens combined [2]. Clinical symptoms usually start with a sudden onset of vomiting and diarrhoea which may last for up to 72 h. However, virus can be shed for up to two months in healthy individuals or longer in immunocompromised people [3,4]. More importantly, 20–50% of NoV infections are asymptomatic [5–7]. Outbreaks often occur in closed settings such as hospitals, cruise ships and long-term care facilities, where transmission is facilitated by contaminated surfaces and aerosolized vomits. These factors, as well as a low infectious dose (~18 particles) [8], high viral load (up to 1010 RNA copies/g of stool) [7,9] and the fact that shedding can precede the onset of symptoms [4] explain the high attack rates. Safe and effective antiviral agents may help to significantly reduce viral shedding and secondary transmission, thereby providing an additional measure to control NoV outbreaks.

The development of antiviral agents and vaccines against human NoV has been hampered by the lack of a cell culture system [10,11]. However, the discovery of murine norovirus (MNV) [12], and the development of Norwalk virus (NV) replicon-bearing cells [13] has partially overcome this problem. The similarity in genome organization and replication strategy to
human NoVs, and the ability to replicate in RAW 264.7 cells, make MNV a candidate to evaluate the efficacy of antiviral agents [14–16]. The NV replicon was established in Huh-7 cells by transfecting RNA transcripts derived from full length NV genome in which VP1 coding region was replaced with a neomycin phosphotransferase gene (NPT II) as a selectable marker [13]. Both the replication of MNV in RAW 264.7 cells and NV replicon-bearing cells have been used successfully to study broad-spectrum antivirals such as interferon (IFN)-α, IFN-γ and ribavirin (RBV), flavonoids-type compounds and phosphorodiamidate morpholino oligomers (PPMO) [17–20].

NoVs are non-enveloped, single stranded, positive sense RNA viruses (ssRNA+) which can be divided into five genogroups (GI–GV) and at least 32 genotypes [21]. The NoV genome (7.5–7.7 kilobases) contains three open reading frames (ORFs), whereas a fourth putative ORF has been described in MNV strains [22]. ORF1 encodes a large polyprotein that is post-translationally cleaved into six non-structural proteins (N-terminal protein-NTPase-p22-Vpg-Protease-RdRp) involved in viral replication [23]. ORF2 and ORF3 encode the major (VP1) and minor (VP2) structural proteins, respectively, both of which are translated from a subgenomic RNA generated during replication [14].

The significant genetic diversity in VP1 represents a major challenge when developing effective vaccines against human NoVs [24,25]. In contrast, non-structural proteins, including protease and RdRp, are more conserved among NoV strains. Crystallographic, functional and sequence analysis studies have demonstrated that the RdRp from different NoV genogroups have similar three-dimensional structures and replication properties [14] making nucleoside analogues attractive drugs for the treatment of these viruses.

The majority of licensed antiviral compounds currently available for medical use against other human viruses, such as HIV and HBV, are nucleoside and non-nucleoside analogue inhibitors that target viral reverse transcriptase [26]. In this study, we determined the antiviral activity of four low molecular weight nucleoside analogue molecules against NoVs using the NV replicon-bearing cells and MNV. We also evaluated the antiviral activity of these compounds in combination with RBV.

Methods

Compounds

Lamivudine (3TC; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl) pyrimidin-2(1H)-one), 2-F-2′-C-MeC (PSI-6130; 4-amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyleraohydrofuran-2-yl) pyrimidin-2(1H)-one), 2′-C-MeC (NM-107; 4-amino-1-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl) pyrimidin-2(1H)-one) and NHC (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-(hydroxyamino) pyrimidin-2(1H)-one) were provided by RFS Pharma, LLC (Tucker, GA, USA). The nucleosides were dissolved in DMSO as 40 mM stock solutions and stored at -80°C until use. RBV was purchased from Sigma (St Louis, MO, USA) and prepared as a 100 mM solution in water (Figure 1).

Cells and virus

HG23 cells (Huh-7-based NV replicon-bearing cells) were kindly provided by Kyeong-Ok Chang, Kansas State University (Manhattan, KS, USA) and propagated in Dulbecco’s modified Eagle medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone Laboratories, Logan, UT, USA), 1% non-essential amino acids (GIBCO, Carlsbad, CA, USA), penicillin (100 units/ml), streptomycin (100 µg/ml) and 0.5–1 mg/ml Geneticin® (Invitrogen, Carlsbad, CA, USA). During the evaluation of the antiviral compounds, cells were incubated with the same media without Geneticin®. Huh-7 cells (kindly provided by Jihong Meng, Centers for Disease Control and Prevention [CDC], Atlanta, GA, USA) were maintained as described previously [13]. RAW 264.7 cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle medium containing 10% fetal bovine serum, 1% sodium pyruvate, 1% HEPES, 1% non-essential amino acids, penicillin (100 units/ml) and streptomycin (100 µg/ml); maintenance medium. MNV (MNV-LCW3) was kindly provided by Herbert Virgin (Washington University, St Louis, MO, USA).

Cytotoxicity assays

Huh-7, HG23 and RAW 264.7 cells were seeded at 1×10⁵, 1×10⁶ and 3×10⁵ cells/well, respectively, in 96-well plates in the presence of 10-fold increasing concentrations (0.1 to 100 µM) of each compound in triplicate, and incubated at 37°C and 5% CO₂ for 5 days. Cell metabolism and proliferation were measured using the Cytotox 96 Non-radioactive Cytotoxicity assay (Promega, Madison, WI, USA) and MTT proliferation assay (Promega) as recommended by the manufacturer. Cytotoxicity levels were expressed as the concentration that inhibited cell growth by 50% (CC₅₀).

Norwalk virus replicon assay

To obtain single compound dose-response curves, HG23 cells were seeded at a density of 1.6×10⁴ cells/well in 96-well plates and incubated at 37°C and 5% CO₂ overnight. 3TC, 2′-F-2′-C-MeC, 2′-C-MeC and NHC were tested at concentrations ranging from 0.1 to 100 µM and RBV was tested from 10 to 200 µM. Compounds were added in triplicate to 80–90%...
confluent monolayers and incubated at 37°C and 5% CO₂. Untreated cells were included in each plate. At 24, 48, 72 and 96 h post-treatment, total RNA was extracted using the Mag-Max Total RNA Isolation kit (Ambion, Austin, TX, USA), and NV replicon RNA was quantified by GI NoV Taqman real-time RT-PCR (NoV RT-qPCR). Protein expression levels were monitored by western blot analysis.

**MNV assay**

To obtain dose-response curves, dilution series of each compound (see Norwalk virus replicon assay section) were added to confluent monolayers of RAW 264.7 cells in 96-well plates in triplicate. After 4 h at 37°C and 5% CO₂, medium was removed and MNV was added at a multiplicity of infection of 4. Untreated wells of infected cells (virus controls) and uninfected cells (cell controls) were included in each plate. After 1 h, virus was removed and 100 μl of maintenance medium was added. After 12, 24, 48 and 72 h post-treatment, total RNA was extracted and analysed for MNV RNA using MNV Taqman real-time RT-PCR. MNV infectivity was titrated by 50% tissue culture infectious dose (TCID₅₀) and the Reed and Munch method [27].

**GI NoV and MNV Taqman real-time RT-PCRs**

GI NoV and MNV Taqman real-time RT-PCRs were performed as described previously [30,31]. A standard curve consisting of 10-fold serial dilutions of NoV GI.4 T7 RNA transcripts or MNV T7 RNA transcripts were included in each experiment [32]. To express the antiviral effectiveness, the threshold RT-PCR cycle of the test compound (Cₜₜₜₜ) was subtracted from the average threshold RT-PCR cycle of the untreated cells (Cₜₜₜₜₜₜₜ). A ΔCₜ (Cₜₜₜₜₜₜₜ - Cₜₜₜₜₜₜₜ) of 3.3 equals 1 log₁₀ reduction in NoV (NV or MNV) RNA levels. The median and 90% effective concentration values

**Figure 1. Chemical structures of 3TC, 2′-F-2′-C-MeC, 2′-C-MeC, NHC and RBV**

<table>
<thead>
<tr>
<th>3TC</th>
<th>2′-F-2′-C-MeC</th>
<th>2′-C-MeC</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="3TC" /></td>
<td><img src="image" alt="2′-F-2′-C-MeC" /></td>
<td><img src="image" alt="2′-C-MeC" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NHC</th>
<th>RBV</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="NHC" /></td>
<td><img src="image" alt="RBV" /></td>
</tr>
</tbody>
</table>

NHC, β-D-N(4)-hydroxycytidine; RBV, ribavirin; 3TC, lamivudine.

Nucleoside analogues in combination with RBV

HG23 cells were seeded in 96-well cell culture plates (1.6×10⁴ cells/well). A matrix of stock solutions containing combinations of 2′-C-MeC or NHC (0, 0.1, 1, 10 and 100 μM) and RBV (0, 10, 20, 50 and 100 μM) was prepared in a 96-well plate and assays were conducted essentially as described above for HG23 cells, except that the compounds were added in a checkerboard format in triplicate. At 24, 48, 72 and 96 h post-treatment, total RNA was extracted and analysed for NV RNA using NoV RT-qPCR and MNV RT-qPCR. Combination effects between 2′-C-MeC or NHC and RBV were calculated by MacSynergy II using the Bliss independence model [28,29].
(EC\textsubscript{50} and EC\textsubscript{90}, respectively) were the concentrations that resulted in 50% and 90% reduction of NoV RNA and were determined using SPSS software [33].

### Western blot analysis

Huh-7 and HG23 cell lysates from treated and untreated wells were prepared in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer containing 1% β-mercaptoethanol. Proteins were resolved in a 12% acrylamide gel (Bio-Rad, Hercules, CA, USA) and transferred to a nitrocellulose membrane. Membranes were probed with rabbit antiserum specific for NPT II (Milipore, Temecula, CA, USA) and peroxidase-conjugated goat anti-rabbit IgG (KPL, Gaithersburg, MD, USA). Protein concentration between wells was normalized using peroxidase-conjugated β-actin-specific monoclonal antibodies (Sigma). Following incubation with a SuperSignal West Pico chemiluminescent substrate (Pierce Bio-technology, Rockford, IL, USA), signals were recorded using AlphaView 3.2.3 (Cell Bioscience, Santa Clara, CA, USA). The concentration that resulted in 50% reduction of NPT II expression (IC\textsubscript{n0}) was determined using SPSS software [33]. Statistical analysis was performed using Student’s t-test. Results were considered statistically significant when the P-value was <0.001.

### Results

Compounds have no cytotoxic effect on cells

To evaluate whether 3TC, 2’-F-2’-C-MeC, 2’-C-MeC and NHC were cytotoxic, Huh-7, HG23 and RAW 264.7 cells were incubated in the presence of increasing concentrations of each compound in two different assays. All CC\textsubscript{50}s were >100 μM, the highest concentration tested (Table 1), indicating that all compounds were well tolerated by the cell lines used for these experiments.

2’-C-MeC and 2’-F-2’-C-MeC significantly reduce MNV RNA levels in RAW 264.7 cells

The antiviral activity of 3TC, 2’-F-2’-C-MeC, 2’-C-MeC and NHC was assessed by growing MNV (MNV-1.CW3) in RAW 264.7 cells in the presence of increasing concentrations of each nucleoside. 2’-C-MeC demonstrated a dose- and time-dependent reduction of MNV RNA levels, whereas, 2’-F-2’-C-MeC showed dose-dependent antiviral activity only at 12 h post-treatment (Figure 2). Neither 3TC nor NHC had antiviral activity against MNV (Additional file 1). The EC\textsubscript{50} and EC\textsubscript{90} of
Two nucleosides, 2′-C-MeC and 2′-F-2′-C-MeC, were evaluated for their antiviral activity against murine norovirus (MNV). A single-compound dose–time–response curve was used to determine the antiviral activity of these compounds. The EC50 and EC90 values for 2′-C-MeC were 6.9 ± 3.9 µM and 25.6 ± 3.7 µM, respectively, at 24 h post-treatment. After 72 h of exposure, MNV RNA levels were reduced by 2 log10 with 0.1 µM 2′-C-MeC. At the highest concentration tested (100 µM), 2′-C-MeC inhibited MNV replication by 3 log10 at 24 h post-treatment.

Treatment of RAW 264.7 cells with 2′-F-2′-C-MeC at concentrations above 1 µM reduced the expression of MNV RNA in a dose-dependent manner. However, antiviral activity was not observed after 12 h regardless of 2′-F-2′-C-MeC concentration (Figure 2). The EC50 and EC90 were 12.7 ± 2.9 µM and 91.2 ± 2.8 µM at 12 h post-treatment (Table 1). RBV also reduced MNV RNA levels in a dose-dependent manner at 12 h and 24 h post-treatment. However, at 24 h post treatment, MNV RNA levels in RBV-treated and non-treated cells were similar. The EC50 for RBV was 63.5 ± 2.3 µM at 12 h post treatment. In the presence of 104.7 ± 1.5 µM RBV, 1 log10 reduction in MNV RNA levels was achieved 24 h after virus treatment.

When the antiviral activities of each nucleoside analogue against MNV were compared, 2′-C-MeC was twofold more potent than 2′-F-2′-C-MeC and markedly more potent than RBV. Both, 2′-C-MeC and 2′-F-2′-C-MeC showed high selectivity index (Table 1). Decrease in MNV RNA levels correlate with reduction in infectivity. The antiviral activity of 3TC, 2′-F-2′-C-MeC, 2′-C-MeC and NHC was evaluated by measuring MNV infectivity in RAW 264.7 cells by TCID50. MNV titres for cells subject to antiviral treatment that were significantly reduced (P < 0.05) compared to untreated, MNV-infected cells (0 µM) are indicated ±12 h; ±24 h and ±48 h. Each point represents the mean ± standard deviation of three replicate experiments (antiviral treatment) and three independent TCID50 assays.

**Figure 2.** Single compound dose– and time–response curves for inhibition of MNV replication in RAW 264.7 cells.

- **A** 2′-F-2′-C-MeC
- **B** 2′-C-MeC
- **C** 2′-F-2′-C-MeC
- **D** 2′-C-MeC

One-day-old semiconfluent RAW 264.7 cells were incubated with increasing concentrations (0.1 µM to 100 µM) of each compound for 4 h, after which the media was removed and murine norovirus (MNV) was added to the cells. Reduction of MNV RNA levels in a dose-dependent manner. However, at concentrations above 1 µM reduced the expression at 24 h post-treatment.

The antiviral activity of 3TC, 2′-F-2′-C-MeC, 2′-C-MeC and NHC was evaluated by measuring MNV infectivity in RAW 264.7 cells by TCID50. MNV titres for cells subject to antiviral treatment that were significantly reduced (P < 0.05) compared to untreated, MNV-infected cells (0 µM) are indicated ±12 h; ±24 h and ±48 h. Each point represents the mean ± standard deviation of three replicate experiments (antiviral treatment) and three independent TCID50 assays.
2′-C-MeC at 10 μM resulted in a significantly lower MNV titre in treated compared to non-treated RAW 264.7 cells at 12 h post-treatment (P<0.001) and continue until 48 h post-treatment. The IC_{50} was 15.7 ±1.2 μM at 12 h post-treatment. At 100 μM, 2′-C-MeC inhibited MNV replication by 99% at 24 h post-treatment. MNV titres were inversely correlated with ΔCt in treated cells at 12 h (Pearson correlation coefficient [r] = -0.546; P=0.033), 24 h ([r] = -0.785; P=0.001) and 48 h ([r] = -0.675; P=0.008).

Treatment of RAW 264.7 cells with 2′-F-2′-C-MeC at 100 μM significantly reduced the infectivity of MNV. The IC_{50} was 33.91 ±1.1 μM at 12 h post-treatment. However, after 12 h, MNV infectivity in treated and non-treated cells was similar. 2′-C-MeC was twofold more potent than 2′-F-2′-C-MeC as measured by IC_{50}.

2′-C-MeC and NHC significantly reduce NV RNA levels in replicon cells

The antiviral activity of 3TC, 2′-F-2′-C-MeC, 2′-C-MeC and NHC was evaluated by growing HG23 cells in the presence of increasing concentrations of each compound. At 24, 48, 72 and 96 h post-treatment, the inhibitory activity of each compound was evaluated by RT-qPCR and western blot. The addition of 2′-F-2′-C-MeC, 2′-C-MeC and NHC to HG23 cells resulted in a dose- and time-dependent reduction of NV RNA levels, whereas 3TC did not show antiviral activity against the NV replicon bearing cells (Figure 3 and Additional file 1).

Treatment with 2′-F-2′-C-MeC resulted in an EC_{50} and EC_{90} of 3.2 ±1.5 μM and 49.0 ±2.9 μM, respectively, at 96 h post-treatment. The EC_{50} of 2′-C-MeC was 1.3 ±0.8 μM, comparable to the antiviral activity of NHC (EC_{50}: 1.5 ±1.1 μM). The EC_{90} was 8.9 ±1.5 μM and 16.6 ±2.1 μM for 2′-C-MeC and NHC, respectively. 2′-C-MeC and NHC were twofold more potent than 2′-F-2′-C-MeC (EC_{50}: 3.2 ±1.5 μM) and 12- to 30-fold more potent than RBV (EC_{50}: 40.0 ±2.3 μM). A high therapeutic index was observed for 2′-C-MeC, NHC and 2′-F-2′-C-MeC (>77.5, >68.0 and >31.4, respectively). More importantly, the therapeutic indexes of 2′-C-MeC, NHC and 2′-F-2′-C-MeC were higher than RBV for both MNV and NV (Table 1).

Reduction of NV RNA levels by both 2′-C-MeC and NHC was observed after 24 h and continued through 96 h. Interestingly, at the two lowest concentrations of 2′-C-MeC (0.1 and 1 μM) a 2.5 log_{10} reduction of the NV RNA level was detected after 96 h, whereas no significant reduction was detected at 24 h and 48 h. Similarly, 1.2 and 3.6 log_{10} reductions in NV RNA were detected at 72 h and 96 h post-treatment, respectively, with 10 μM 2′-C-MeC.

Because 2′-C-MeC and NHC were significantly more potent than the other compounds, antiviral activity against NV was further verified using western blot assay to measure the expression of NPT II (Figure 3). 2′-C-MeC treatment reduced NPT II expression to 83%, 13% and 2% of untreated cells at 1, 10 and 100 μM, respectively, while treatment with 1, 10 and 100 μM NHC reduced the expression of NPT II to 91, 40 and 16% of untreated cells, respectively.

Ribavirin and 2′-C-MeC interacted synergistically on NV replicon cells, but NHC was antagonistic

In the present study, 2′-C-MeC and NHC were identified as the most potent antiviral agents against replication of NV in HG23 cells. We further evaluated whether combinations of 2′-C-MeC or NHC with RBV could enhance the antiviral effect (Figure 4 and Additional file 1). A modest synergistic effect was observed at 24 h post-treatment for 2′-C-MeC concentrations above 10 μM in combination with RBV below 20 μM (Figure 4A). After 24 h treatment, the antiviral activity of this combination appears to be additive or slightly antagonistic (Figure 4B and Additional file 1). The combination of NHC and RBV resulted in an additive antiviral effect with a slight tendency toward antagonistic activity at 24 h and 48 h post-treatment (Figure 4C and 4D and Additional file 1). No cytotoxicity was observed for the 2′-C-MeC/RBV or NHC/RBV combinations at antiviral concentrations (data not shown).

Discussion

NoV gastroenteritis is a major public health burden, in particular, in vulnerable populations. Broad spectrum antivirals such as RBV, IFN-α and IFN-γ have been shown to inhibit NoV replication [17]. However the high EC_{50} for reducing NV RNA resulting in a narrow therapeutic index (SI) and the reported adverse effects associated with treatment make these compounds unsuitable for treatment. On the other hand, orally bioavailable antiviral compounds, such as nucleoside analogues, that specifically target viral enzymes have shown antiviral activity against several ssRNA+ viruses [34–38]. As part of the effort to develop antivirals against RNA viruses, 2′C-methyl branched pyrimidine ribonucleosides have been identified as potent inhibitors against members of the Flaviviridae family, such as HCV [36,37,39]. The success of these antivirals against HCV and other ssRNA+ viruses prompted us to evaluate their antiviral activity against NoVs.

Three of the compounds (2′-C-MeC, 2′-F-2′-C-MeC and NHC) significantly reduced NV RNA levels in HG23 cells, whereas 2′-C-MeC and 2′-F-2′-C-MeC also reduced RNA levels and infectivity of MNV in a concentration- and time-dependent manner. 2′-C-MeC has also demonstrated antiviral activity against pestiviruses, flaviviruses, coronaviruses and enteroviruses.
Figure 3. Single compound dose- and time response curves for inhibition of NV replication in HG23 cells

One-day-old semiconfluent HG23 cells were incubated with increasing concentrations (0.1 μM to 100 μM) of each nucleoside. Reduction of Norwalk virus (NV) RNA levels at 24 h (represented by an open diamond), 48 h (represented by an open square), 72 h (represented by a black square) and 96 h (represented by a black diamond) after treatment with (A) 2′-C-MeC or (B) β-D-N(4)-hydroxycytidine (NHC) were quantified by RT-qPCR. To express antiviral effectiveness, the mean Ct value of the no-drug control cells (Ctno drug) was subtracted from the mean Ct value from treated wells (Ct drug). A ΔCt of 3.3 equals 1-log reduction in norovirus RNA levels (90% effective concentration). Each point represents the mean ± standard deviation of three replicate experiments (antiviral treatment) and three independent RT-qPCR runs. Effect of (C) 2′-C-MeC or (D) NHC on the expression of neomycin phosphotransferase II (NPT II) detected by western blot analysis after 72 h incubation. Expression of NPT II and NPT-II fused to truncated VP1 (NPT II-tVP1) was measured as previously described [13,17]. Huh-7 cells were included as negative control for NPT II expression. Band intensities were normalized against β-actin and expressed as a percentage of the untreated HG23 cells intensity. aNPT II levels for cells treated with (E) 2′-C-MeC or (F) NHC that were significantly (P<0.001) different from cells without treatment.
Our results show that EC_{50} values for NV and MNV (1.3–6.9 μM) are in the same range as those for HCV and bovine viral diarrhoea virus (BVDV; 2–7 μM), and 2′-C-MeC is also 8- to 60-fold more active against NoV than against other ssRNA + viruses [38]. 2′-F-2′-C-MeC inhibits HCV, but not BVDV replication [35]. 2′-F-2′-C-MeC was 1.4 and 3.3-fold more active against NV than against HCV and MNV, respectively. NHC is active against HCV, BVDV [36] and NV, but not MNV (this study). Unfortunately, NHC has mutagenic properties [36] and cannot be used as a safe drug against viral infections in humans.

Figure 4. Antiviral effect of the combination of RBV with 2′-C-MeC at 24 h and 48 h, or RBV with NHC at 24 h and 48 h in HG23 cells

Concentrations of each compound are indicated on the x- and y-axes. Area above the zero plane on the z-axis indicates doses of each compound that are synergistic, the zero plane indicates doses that are additive and the volume below indicates doses that are antagonistic. Different shades represent different ranges of values.

Data for the combinations are the mean value for five experiments (99% CI). (A) Ribavirin (RBV) with 2′-C-MeC at 24 h and (B) 48 h, or (C) RBV with β-D-N(4)-hydroxycytidine (NHC) at 24 h and (D) 48 h in HG23 cells.
Previous reports showed that RBV, IFN-α and 2-styrylchromones inhibited replication of NV and/or MNV [17,19,20]. In our study, 2′-C-MeC (EC\text{50} 1.3 μM), 2′-F-2′-C-MeC (EC\text{50} 3.2 μM) and NHC (EC\text{50} 1.5 μM) were 30-, 12- and 27-fold more potent than RBV against NV, respectively, while 2′-C-MeC and 2′-F-2′-C-MeC were 4- to 7-fold more potent, respectively, that RBV against MNV. 2′-C-MeC and 2′-F-2′-C-MeC showed IC\text{50} in the same range (15.7 μM and 33.9 μM, respectively) as 2-styrylchromones [19]. Interestingly, the SI of 2-styrylchromones are higher than those for 2′-C-MeC and 2′-F-2′-C-MeC, likely because the highest antiviral concentration tested in our study (100 μM) was lower than described for the 2-styrylchromones (150 μM), directly affecting SI. Overall, the lower EC\text{50} and consequently higher SI, makes 2′-C-MeC a good candidate for further study. The antisense approach (PMMO) has also been evaluated as antiviral treatment showing that 3 μM of a Noro1.1 was sufficient to reduce total protein translation by 80% or more in a luciferase reporter assay system [18]. In our study, the IC\text{50} for 2′-C-MeC and NHC was in the same range as the Noro1.1. However, the poor cell permeability of PMMO and nucleoside analogues is a major limitation when testing these compounds. Furthermore, administration of PMMOs requires an injection, whereas nucleosides are usually administered orally.

High viral load, prolonged virus shedding and genetic drift are characteristics associated with NoV infections [3,4,9]. These factors have been associated with the emergence of resistance against antivirals in other viral infections which has led to the application of combined antiviral therapies [40]. Combination of antiviral agents may result in additive, synergistic or antagonistic activity depending on their mechanisms of action. The 2′-C-MeC/RBV combination showed initial modest synergistic activity (2′-C-MeC>10 μM, RBV<20 μM), whereas longer exposure times resulted in additive or slightly antagonistic activity. Similarly, the NHC/RBV combination resulted in mostly additive activity. RBV has been reported to reduce NV RNA and protein expression in HG23 cells by blocking inosine monophosphate dehydrogenase [17], whereas nucleoside analogue inhibitors may act as chain terminators of nucleotide polymerization or by disruption of the polymerase active site [38,41,42]. Similar to the results in our study, the combination RBV/IFN-α (2 IU/ml) showed additive activity against NV [17]. However, it remains unclear why the 2′-C-MeC/RBV and NHC/RBV combinations showed early synergistic or antagonistic activity, respectively. Previous studies have demonstrated that the outcome of a combination therapy will depend on the drug, the concentration and virus strain [40]. RBV has shown additive activity with purine-based deoxynucleoside analogue inhibitors against HBV, but in combination with pyrimidine ribonucleoside analogue inhibitors demonstrated antagonistic activity against HCV [43].

The broad anti-NoV activity and lower EC\text{50} of 2′-C-MeC (compared with 2′-F-2′-C-MeC and NHC), was demonstrated for NoV strains belonging to two different genogroups (GI and GV). Although we did not evaluate a GI NoV strain which cause the majority of the outbreaks [44], our data suggest that 2′-C-MeC could be effective across genogroups. Although there is a 40% amino acid difference between the MNV-RdRp (GV) and human NoV-RdRp (GII) [14], both share the same overall structure, organization of domains and mechanisms for initiation of RNA replication (de novo or protein-powered) [45–47]. These observations together with the fact that 2′-C-MeC was able to reduce RNA levels from both GI and GV, suggest that this nucleoside analogue is a strong candidate for testing against additional human NoV strains.

Development and selection of effective antiviral treatment requires additional studies including assessing oral bioavailability, stability of the drug in plasma, delivery, cell permeability and biological activation. In closed settings such as cruise or military ships, or high health risk populations like hospitals or nursing homes, safe antiviral agents could be an effective method to control the spread of human NoV regardless of the immune status of the population. In this study, we identified three compounds that may help to reduce and control NoV shedding. Further studies are required to investigate the possible emergence of antiviral resistance and to determine compound activity in vitro. Reportedly, both 2′-C-Me-cytidine nucleosides have advanced to Phase II clinical trials for HCV infections. A prodrug of 2′-C-MeC (NM-283) was found to have gastrointestinal problems and was abandoned for the treatment of HCV. However, a prodrug of 2′-F-2′-C-MeC (RG-7128 or mericitabine) demonstrated safety and efficacy against HCV and is poised to enter Phase III clinical trials suggesting that this class of compound could also be developed for NoV infections. In addition, since the duration of treatment may be much shorter than for HCV infections, the safety of these nucleoside analogues could be higher, especially if given prophylactically for the prevention of NoV infections.

**Acknowledgements**

This study was partially supported by a grant from CDC Foundation. RFS’s salary is partly supported by the Atlanta Department of Veterans Affairs and by CFAR grant 2P30-Al-050409.

The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
article did receive clearance through the appropriate channels at the CDC prior to submission.

Disclosure statement
RFS is the principal founder, Director and major shareholder of RFS Pharma, LLC. He is also a founder and shareholder of Idenix Pharmaceuticals and Pharmasset, Inc. All of his conflicts of interest were reviewed and are managed primarily by Emory University School of Medicine, and the Department of Veterans Affairs. All other authors declare no competing interests.

Additional file
Additional file 1: Supplementary figures providing more data can be found at http://www.intmedpress.com/uploads/documents/AVT-11-OA-2327_Costantini_Add_file1.pdf

References


